Okyo Pharma LTD (OKYO) — SEC Filings

Overview

Okyo Pharma LTD (OKYO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 7, 2026: OKYO Pharma Ltd filed a Form 6-K on April 7, 2026, reporting information as a foreign issuer. The filing includes the 6-K form itself, an exhibit EX-99.1, and a graphic file. The company's mailing and business address is listed as 55 Park Lane, London, UK.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 16 bullish, 1 bearish, 33 neutral. The dominant filing sentiment for Okyo Pharma LTD is neutral.

Filing Type Overview

Okyo Pharma LTD (OKYO) has filed 47 6-K, 1 20-F/A, 2 20-F with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• OKYO Pharma Files 6-K Report — 6-K · Apr 7, 2026 Risk: low
  OKYO Pharma Ltd filed a Form 6-K on April 7, 2026, reporting information as a foreign issuer. The filing includes the 6-K form itself, an exhibit EX-99.1, and a
• OKYO Pharma Rings Nasdaq Opening Bell — 6-K · Dec 19, 2025 Risk: low
  On December 19, 2025, OKYO Pharma Ltd announced that Executive Chairman and Founder, Gabriele Cerrone, along with the management team, will ring the Opening Bel
• 6-K Filing — 6-K · Dec 15, 2025
• 6-K Filing — 6-K · Dec 11, 2025
• 6-K Filing — 6-K · Dec 3, 2025
• 6-K Filing — 6-K · Nov 21, 2025
• 6-K Filing — 6-K · Nov 18, 2025
• OKYO Pharma CEO to Speak at BIO-Europe Conference — 6-K · Oct 29, 2025 Risk: low
  On October 29, 2025, OKYO Pharma Ltd announced that its CEO, Gary S. Jacob, Ph.D., will present at the 33rd Annual BIO-Europe partnering conference in Vienna, A
• OKYO Pharma: Chairman's Entity Buys 210K Shares — 6-K · Oct 16, 2025 Risk: low
  On October 16, 2025, OKYO Pharma Ltd announced that Panetta Partners Limited, an entity with a beneficial interest held by Executive Chairman Gabriele Cerrone,
• OKYO Pharma Starts 100-Patient Trial for Urcosimod — 6-K · Sep 22, 2025 Risk: medium
  On September 22, 2025, OKYO Pharma Ltd announced the initiation of a 100-patient, multi-center clinical trial for Urcosimod to treat Neuropathic Corneal Pain. T
• OKYO Pharma Amends 20-F/A to Include Clawback Policy — 20-F/A · Aug 12, 2025 Risk: low
  OKYO Pharma Ltd filed an Amendment No. 1 on Form 20-F/A on August 12, 2025, for the fiscal year ended March 31, 2025. This amendment's sole purpose was to revis
• OKYO Pharma Navigates Pre-Revenue Phase, Bolsters Capital for R&D — 20-F · Jul 18, 2025 Risk: high
  OKYO Pharma Ltd reported no revenue for the fiscal year ended March 31, 2025, consistent with its pre-commercialization stage as a biotechnology company. The co
• OKYO Pharma Secures $1.9M Non-Dilutive Funding — 6-K · Jul 17, 2025 Risk: medium
  On July 17, 2025, OKYO Pharma LTD announced it secured $1.9 million in non-dilutive funding. This capital injection is designated to advance the company's resea
• OKYO Pharma Announces Positive Phase 2 Data for Urcosimod — 6-K · Jul 16, 2025 Risk: medium
  On July 16, 2025, OKYO Pharma Ltd announced positive top-line data from its 18-patient Phase 2 trial for urcosimod (formerly OK-101) to treat Neuropathic Cornea
• OKYO Pharma CEO to Present on Urcosimod at Bio International Convention — 6-K · Jun 11, 2025 Risk: low
  On June 11, 2025, OKYO Pharma Ltd announced that its CEO, Gary S. Jacob, Ph.D., will present on the development of urcosimod at the Bio International Convention
• OKYO Pharma CEO to Present at GPCR Drug Discovery Summit — 6-K · May 19, 2025 Risk: low
  On May 19, 2025, OKYO Pharma Ltd announced that its CEO, Gary S. Jacob, Ph.D., will present at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA
• OKYO Pharma's Urcosimod Gets FDA Fast Track for Pain — 6-K · May 1, 2025 Risk: medium
  On May 1, 2025, OKYO Pharma Ltd announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its drug candidate, urcosimod.
• OKYO Pharma Accelerates Urcosimod Development for NCP — 6-K · Apr 30, 2025 Risk: medium
  OKYO Pharma Ltd announced on April 30, 2025, that it will accelerate the clinical development of its drug urcosimod for treating NCP. This decision follows an a
• OKYO Pharma's Urcosimod Shows Long-Term Stability — 6-K · Mar 31, 2025 Risk: low
  On March 31, 2025, OKYO Pharma Ltd announced that its drug candidate, urcosimod (formerly OK-101), has demonstrated stability for over two and a half years when
• OKYO Pharma Seeks FDA Fast Track for Neuropathic Pain Drug — 6-K · Mar 10, 2025 Risk: medium
  On March 10, 2025, OKYO Pharma Ltd announced it has filed an application with the U.S. Food and Drug Administration (FDA) for Fast Track designation for its dru
• OKYO Pharma's OK-101 Asset Named Urcosimod — 6-K · Feb 12, 2025 Risk: low
  On February 12, 2025, OKYO Pharma Ltd announced that its lead asset, OK-101, has been officially assigned the United States Adopted Name (USAN) "urcosimod". Thi
• OKYO Pharma CEO Buys Shares — 6-K · Jan 31, 2025 Risk: low
  On January 31, 2025, OKYO Pharma Ltd announced that its CEO, Gary S. Jacob, purchased 10,000 ordinary shares on NASDAQ at $1.04 per share. This purchase was mad
• OKYO Pharma Ltd Reports H1 2024 Financials and Business Update — 6-K · Jan 29, 2025 Risk: low
  OKYO Pharma Ltd announced its financial results for the six-month period ending September 30, 2024, on January 29, 2025. The company, headquartered in London, a
• OKYO Pharma Secures $1.4M Non-Dilutive Funding — 6-K · Jan 22, 2025 Risk: low
  On January 22, 2025, OKYO Pharma Ltd announced it has secured $1.4 million in non-dilutive funding. This capital infusion will support the advancement of the co
• OKYO Pharma CEO to Speak at BTIG Ophthalmology Day — 6-K · Nov 26, 2024 Risk: low
  OKYO Pharma Ltd announced on November 26, 2024, that its CEO, Gary S. Jacob, Ph.D., will participate in the 4th Annual Virtual BTIG Ophthalmology Day on Decembe
• OKYO Pharma to Present at Ocular Surface Conference — 6-K · Oct 30, 2024 Risk: low
  OKYO Pharma Ltd announced on October 30, 2024, that its management team will present at the 10th International Tear Film & Ocular Surface Society Conference in
• OKYO Pharma Doses First Patient in OK-101 Phase 2 NCP Trial — 6-K · Oct 23, 2024 Risk: medium
  On October 23, 2024, OKYO Pharma Ltd announced that the first patient has been dosed in its Phase 2 clinical trial for topical ocular OK-101, a treatment for Ne
• OKYO Pharma Starts Phase 2 Trial for OK-101 — 6-K · Oct 16, 2024 Risk: medium
  On October 16, 2024, OKYO Pharma Ltd announced the commencement of patient screening and recruitment for a Phase 2 clinical trial of its drug OK-101. This trial
• OKYO Pharma: Chairman's Entity Buys 50,000 Shares — 6-K · Sep 10, 2024 Risk: medium
  On September 10, 2024, OKYO Pharma Ltd announced that Panetta Partners Limited, an entity with a beneficial interest held by Executive Chairman Gabriele Cerrone
• OKYO Pharma: Chairman's associate buys 80,000 shares — 6-K · Sep 5, 2024 Risk: low
  On September 5, 2024, OKYO Pharma Ltd announced that Panetta Partners Limited, an entity associated with Executive Chairman Gabriele Cerrone, acquired 80,000 or
• OKYO Pharma Secures US Patent for Dry Eye Treatment — 6-K · Aug 27, 2024 Risk: low
  On August 27, 2024, OKYO Pharma Ltd announced the grant of U.S. Patent No. 12,053,501, issued on August 6th, for "Methods for Treating Symptoms of Dry Eye Disea
• OKYO Pharma: Chairman's associate buys 50,000 shares — 6-K · Aug 23, 2024 Risk: low
  On August 23, 2024, OKYO Pharma Ltd announced that Panetta Partners Limited, an entity associated with Executive Chairman Gabriele Cerrone, purchased 50,000 ord
• OKYO Pharma: Chairman's Entity Buys 35,000 Shares — 6-K · Aug 21, 2024 Risk: low
  On August 21, 2024, OKYO Pharma Ltd announced that Panetta Partners Limited, an entity with a beneficial interest held by Executive Chairman Gabriele Cerrone, p
• OKYO Pharma to Participate in H.C. Wainwright Ophthalmology Conference — 6-K · Aug 15, 2024 Risk: low
  OKYO Pharma Ltd announced on August 15, 2024, that it will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The conference is sch
• OKYO Pharma Ltd Files 20-F for FY Ending March 31, 2024 — 20-F · Aug 13, 2024 Risk: medium
  OKYO Pharma Ltd filed its annual 20-F report for the period ending March 31, 2024. The company, based in London, operates in the biological products sector. The
• OKYO Pharma Secures Key European Patent for Chemerin Analogs — 6-K · Aug 6, 2024 Risk: medium
  On August 6, 2024, OKYO Pharma Ltd announced the grant of a key European Patent for "Compositions Comprising Chemerin Analogs and Methods of Use." Raj Patil, Ch
• OKYO Pharma to Start Phase 2 Trial for Neuropathic Corneal Pain — 6-K · Jul 11, 2024 Risk: medium
  OKYO Pharma Ltd announced on July 11, 2024, its intention to initiate a Phase 2 clinical trial for its drug candidate OK-101 to treat neuropathic corneal pain.
• OKYO Pharma Ltd Files New Investor Presentation — 6-K · Jul 10, 2024 Risk: low
  On July 10, 2024, OKYO Pharma Ltd announced the filing of a new investor presentation. This presentation is furnished as Exhibit 99.1 to their Form 6-K filing w
• OKYO Pharma to Present at May Investor Conferences — 6-K · May 8, 2024 Risk: low
  OKYO Pharma Ltd announced on May 8, 2024, that it will be participating in two investor conferences in May 2024. The company, located at 55 Park Lane, London, w
• OKYO Pharma to Present OK-101 Phase 2 Dry Eye Data — 6-K · Apr 30, 2024 Risk: medium
  OKYO Pharma Ltd announced on April 30, 2024, that it will present Phase 2 data for its dry eye disease drug, OK-101, at the Dry Horizons Symposium on May 3, 202
• OKYO Pharma Reschedules KOL Event for OK-101 Phase 2 Trial Results — 6-K · Apr 9, 2024 Risk: medium
  OKYO Pharma Ltd announced on April 8, 2024, that it is rescheduling its Key Opinion Leader (KOL) event. This event was intended to present comprehensive detaile
• OKYO Pharma Ltd. Files 6-K with SEC — 6-K · Apr 4, 2024 Risk: low
  OKYO Pharma Ltd. filed a Form 6-K on April 4, 2024, to report information as a foreign private issuer. The filing indicates the company is based in London, UK,
• OKYO Pharma to Present OK-101 Phase 2 Dry Eye Data — 6-K · Apr 2, 2024 Risk: medium
  OKYO Pharma Ltd announced on April 2, 2024, that it will present Phase 2 data for its dry eye disease treatment, OK-101, at Eyecelerator 2024. This event is a p
• OKYO Pharma Ltd Reports Interim Results — 6-K · Mar 29, 2024 Risk: low
  OKYO Pharma Ltd announced its interim results for the six months ended September 30, 2023, on March 29, 2024. The company, headquartered in London, filed a Form
• OKYO Pharma's OK-101 Trial Shows Success in Dry Eye Disease — 6-K · Mar 22, 2024 Risk: medium
  On March 22, 2024, OKYO Pharma Ltd announced that its Phase 2 trial for OK-101 in treating Dry Eye Disease achieved statistical significance. The drug demonstra
• OKYO Pharma to Host KOL Event for OK-101 Phase 2 Data — 6-K · Mar 21, 2024 Risk: medium
  OKYO Pharma Ltd announced on March 21, 2024, that it will host a Key Opinion Leader (KOL) event on April 9th, 2024, at 12:00 PM ET. The event will focus on disc
• OKYO Pharma to Release Dry Eye Trial Data March 22 — 6-K · Mar 20, 2024 Risk: medium
  OKYO Pharma Ltd announced on March 20, 2024, that it will release new efficacy data from its Phase 2 trial of OK-101 for dry eye disease on March 22, 2024. The
• OKYO Pharma's OK-101 Cleared by FDA for Neuropathic Corneal Pain IND — 6-K · Feb 9, 2024 Risk: medium
  OKYO Pharma Ltd. announced on February 9, 2024, that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for
• OKYO Pharma Adds Top Ophthalmologists to Scientific Advisory Board — 6-K · Jan 31, 2024
  OKYO Pharma Ltd. announced on January 31, 2024, that three distinguished ophthalmologists, Victor Perez, M.D., Anat Galor, M.D., and Mark Milner, M.D., have joi
• OKYO Pharma's OK-101 Hits Key Endpoints in Phase 2 Dry Eye Trial — 6-K · Jan 8, 2024
  OKYO Pharma Ltd. announced on January 8, 2024, that its drug candidate, OK-101, successfully met both sign and symptom endpoints with statistical significance i

Risk Profile

Risk Assessment: Of OKYO's 43 recent filings, 1 were flagged as high-risk, 19 as medium-risk, and 23 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Gabriele Cerrone
• Gary S. Jacob, Ph.D.
• Gary Jacob
• Ed Lukins
• Gary S. Jacob
• Raj Patil
• Keeren Shah

Industry Context

OKYO Pharma operates in the biotechnology and pharmaceutical sector, a highly competitive and research-intensive industry. The sector is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Key trends include advancements in targeted therapies, personalized medicine, and the increasing importance of strategic collaborations and licensing agreements to advance drug pipelines.

Top Tags

drug-development (15) · biotech (14) · clinical-trial (7) · ophthalmology (6) · insider-transaction (4) · share-purchase (4) · sec-filing (3) · conference-presentation (3) · presentation (3) · investor-relations (3)

Key Numbers

• Ordinary Shares Acquired: 210,000 — Acquired by Panetta Partners Limited, an entity associated with the Executive Chairman.
• Patients: 100 — Number of participants in the multi-center clinical trial
• Ordinary Shares Outstanding: 37,610,676 — As of July 3, 2025, indicating the company's current share count.
• Fiscal Year End: 2025-03-31 — The period covered by the amended annual report.
• Amendment Filing Date: 2025-08-12 — Date the 20-F/A was filed with the SEC.
• Original Filing Date: 2025-07-18 — Date the Original Form 20-F was filed.
• Revenue: $0 — for the fiscal year ended March 31, 2025, indicating pre-commercialization stage
• Fiscal Year End Date: 2025-03-31 — period of report for the 20-F filing
• Filing Date: 2025-07-18 — date the 20-F was filed with the SEC
• Non-dilutive funding: $1.9M — To support R&D and clinical development of urcosimod.
• Phase 2 Trial Size: 18-patient — Indicates the scale of the study that yielded positive results.
• Drug Stability: 2.5 years — Demonstrated stability of urcosimod in single-use ampoules.
• Shares Purchased: 10,000 — CEO Gary S. Jacob bought this many shares.
• Price Per Share: $1.04 — The price at which the CEO purchased shares.
• Reporting Period: H1 2024 — Financial results for the six-month period ending September 30, 2024.

Forward-Looking Statements

• {"claim":"OKYO Pharma will initiate Phase 1 clinical trials for OK-101 within the next 6-12 months.","entity":"OKYO Pharma LTD","targetDate":"2025-02-09","confidence":"medium"}
• {"claim":"The stock price of OKYO Pharma will see increased volatility as clinical trial results for OK-101 are anticipated.","entity":"OKYO Pharma LTD","targetDate":"2025-08-09","confidence":"high"}

Frequently Asked Questions